{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:47:12Z","timestamp":1773967632537,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["FNOs\/2025"],"award-info":[{"award-number":["FNOs\/2025"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jacl.2025.11.016","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:27:50Z","timestamp":1764635270000},"page":"444-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improvement of severe hypertriglyceridemia in atypical subtype 4 partial lipodystrophy with volanesorsen"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5350-4191","authenticated-orcid":false,"given":"Pavla","family":"Jadrn\u00ed\u010dkov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luk\u00e1\u0161","family":"Tich\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Ka\u0161pr\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"V\u00e1clav\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6532-7053","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"Freiberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.11.016_bib0001","unstructured":"Akinci B, Gular MC, Oral EA Lipodystrophy syndromes: presentation and treatment. In: Feingold KR, Ahmed SF, Anawalt B, et al., eds. Endotext. MDText.com, Inc.; 2024."},{"issue":"2","key":"10.1016\/j.jacl.2025.11.016_bib0002","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/17446651.2020.1735360","article-title":"Diagnostic strategies and clinical management of lipodystrophy","volume":"15","author":"Foss-Freitas","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jacl.2025.11.016_bib0003","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1758-5996-4-40","article-title":"Body composition study by dual-energy x-ray absorptiometry in familial partial lipodystrophy: finding new tools for an objective evaluation","volume":"4","author":"Valerio","year":"2012","journal-title":"Diabetol Metab Syndr"},{"issue":"5","key":"10.1016\/j.jacl.2025.11.016_bib0004","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/cen.13311","article-title":"Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort","volume":"86","author":"Ajluni","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"10.1016\/j.jacl.2025.11.016_bib0005","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.11.016_bib0006","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronemia syndrome (FCS): expert panel recommendations and proposal of a new clinical scoring system","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.jacl.2025.11.016_bib0007","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/cvr\/cvae005","article-title":"Perilipin 1: a systematic review on its functions on lipid metabolism and atherosclerosis in mice and humans","volume":"120","author":"Desgrouas","year":"2024","journal-title":"Cardiovasc Res"},{"issue":"8","key":"10.1016\/j.jacl.2025.11.016_bib0008","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/dom.14726","article-title":"Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: real-life experience from a national reference network","volume":"24","author":"Mosbah","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.jacl.2025.11.016_bib0009","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study: volanesorsen in FPLD; the BROADEN study","volume":"16","author":"Oral","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2025.11.016_bib0010","article-title":"The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS)","volume":"11","author":"Gaudet","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.11.016_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosissup.2018.04.074","article-title":"Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Gouni-Berthold","year":"2018","journal-title":"Atheroscler Suppl"},{"issue":"6","key":"10.1016\/j.jacl.2025.11.016_bib0012","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacl.2025.11.016_bib0013","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.11.016_bib0014","unstructured":"Protein Atlas. Tissue expression of LPL - summary - the Human Protein Atlas. The Human Protein Atlas. Accessed July 25, 2019. https:\/\/www.proteinatlas.org\/ENSG00000175445-LPL\/tissue."},{"issue":"8","key":"10.1016\/j.jacl.2025.11.016_bib0015","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1007487","article-title":"Perilipin deficiency and autosomal dominant partial lipodystrophy","volume":"364","author":"Gandotra","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jacl.2025.11.016_bib0016","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1210\/jc.2017-02662","article-title":"PLIN1 Haploinsufficiency is not associated with lipodystrophy","volume":"103","author":"Laver","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jacl.2025.11.016_bib0017","doi-asserted-by":"crossref","first-page":"e2318","DOI":"10.1210\/clinem\/dgac104","article-title":"PLIN1 Haploinsufficiency causes a favorable metabolic profile","volume":"107","author":"Patel","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.jacl.2025.11.016_bib0018","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1210\/jc.2019-00849","article-title":"Diagnostic challenge in PLIN1-associated familial partial lipodystrophy","volume":"104","author":"J\u00e9ru","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.jacl.2025.11.016_bib0019","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425005239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425005239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:53:42Z","timestamp":1773960822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425005239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1933287425005239"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.11.016","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement of severe hypertriglyceridemia in atypical subtype 4 partial lipodystrophy with volanesorsen","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}